NicOx and TOPIGEN sign agreement for NCX 1020 in COPD and other respiratory diseases
31-Oct-2005 -
NicOx S.A. and TOPIGEN Pharmaceuticals Inc. announced they have signed a license and
development agreement for NicOx' phase 2a compound, NCX 1020, in Chronic Obstructive Pulmonary Disease (COPD) and other respiratory disorders. NicOx has granted TOPIGEN rights to NCX 1020 in North America, in ...
asthma
immune cells
milestone payments
+6